Investor Relations

<< Back


Glenn R. Larsen, Ph.D.

CEO of Aquinnah Pharmaceuticals, Inc.

Dr. Larsen joined the Board of Directors of Anika Therapeutics in February 2015. He is currently Chief Executive Officer of Aquinnah Pharmaceuticals, Inc., a pharmaceutical company focused on the development of treatments for ALS and neurodegenerative diseases, which he co-founded in February 2014. He also is a co-founder and Chairman of the Board of Directors of 180 Therapeutics L.P., a clinical stage drug delivery and development company founded in 2013. He previously served as Chief Scientific Officer and Executive Vice President of Research and Development at SpringLeaf Therapeutics, Inc., a producer of drug delivery devices, and at Hydra Biosciences, Inc., a biopharmaceutical company, as Chief Operating Officer and Executive Vice President of Research and Development, and as a member of its board of directors. During his prior employment at Wyeth (Pfizer)/Genetics Institute, Dr. Larsen served in various research and development leadership positions, including directing Wyeth's second largest therapeutic area as Vice President Musculoskeletal Sciences. Dr. Larsen received his Ph.D. in Biochemistry from Stony Brook University. Mr. Larsen's qualifications for membership on the Company's Board include his strong scientific background in pharmaceutical, biotech, orthopedics and regenerative medicine, and his extensive experience in management and product development at multiple companies in the life science industry, both of which provide our Board of Directors with innovative product and business development perspectives and insights.